Central Venous Catheter Market Size, Share, & Trends Analysis | Global | 2025-2032 | MedCore | Includes: Acute Central Venous Catheters, and Chronic Central Venous Catheters

Product Description

Overall, the global CVC market was valued at $1 billion in 2025. This is expected to increase over the forecast period at a CAGR of 1.4% to reach $1.1 billion by 2032.

The full report suite on the global market for central venous catheters (CVCs) includes acute CVCs and chronic CVCs. The acute CVC category encompasses both power-injectable and non-power-injectable devices. The chronic CVC category encompasses both power-injectable and non-power-injectable devices, too.

Data Types Included

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Procedure Numbers
• Market Drivers & Limiters
• Market Forecasts Until 2032, and Historical Data to 2022
• Recent Mergers & Acquisitions
• Company Profiles and Product Portfolios
• Leading Competitors

Global Central Venous Catheter Market Trends

The expanding use of PICCs continues to constrain growth in the CVC market, particularly outside of acute care settings. In outpatient and non-critical care environments, PICCs are often favored due to lower infection risk, bedside placement by nursing staff and reduced procedural costs, while covering many of the same clinical indications as CVCs. However, CVCs remain essential in critical care due to their superior flow rates and reliability for high-acuity patients. In chronic care pathways, CVCs face increasing competition from PICCs and, in some cases, step-down strategies that transition patients from CVCs to PICCs and eventually to PIVCs as clinical needs evolve.

Global Central Venous Catheter Market Share Insights

• Teleflex held the leading position in the CVC market in 2025, dominating both the acute and chronic segments. This leadership was established following its acquisition of Arrow International in 2007, which provided a comprehensive range of catheter products. Teleflex entered the chronic CVC market in 2013 with the ARROW® JACC featuring Chlorag+ard® Technology, offering antimicrobial and antithrombogenic properties suitable for both short-term and long-term use. The company primarily represented the triple-lumen subcategory of CVCs and reported robust growth, driven partly by increased CVC sales.
• Becton Dickinson (BD) ranked as the second-leading competitor in the 2025 CVC market, largely due to its presence in the chronic CVC segment. BD’s brands, such as PowerHohn®, Hohn®, PowerLine®, PowerHickman® and Hickman® Trifusion® catheters, have become synonymous with chronic CVCs. Despite a declining growth rate in the chronic CVC market, BD’s established market position and brand recognition have contributed to its significant market share.
• B. Braun secured the third-leading position in the total CVC market in 2025 by focusing primarily on the acute CVC market. Leveraging its strong presence in neighboring markets such as Scandinavia and Switzerland, B. Braun maintained a significant share through its Certofix® and Cavafix® CVC product lines. Notably, B. Braun’s Certofix® Protect line of CVCs, marketed as antimicrobial devices, allowed it to compete effectively in the growing antimicrobial market segment.

Global Central Venous Catheter Market Segmentation Summary

• Central Venous Catheter (CVC) Market – Further Segmented Into:
  • Device Type: Acute Venous Catheters and Chronic Venous Catheters.

Research Scope Summary